share_log

Chimeric Therapeutics Ltd: AML patient achieves Complete Response in CHM CORE-NK trial

ASX ·  Oct 7 06:45
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.